Standard BioTools Inc.
Standard BioTools Inc. (LAB) Revenue
Annual & quarterly revenue history · segment & region breakdown
LAB · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsStandard BioTools Inc. trailing twelve-month (TTM) revenue is $0.09B, a decrease of 51.08% year-over-year from $0.09B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.09B | -$0.09B | -51.08% |
| 2024-12-31 | $0.17B | +$0.07B | +64.03% |
| 2023-12-31 | $0.11B | +$0.01B | +8.57% |
| 2022-12-31 | $0.10B | -$0.03B | -24.99% |
| 2021-12-31 | $0.13B | -$0.01B | -5.47% |
| 2020-12-31 | $0.14B | +$0.02B | +17.83% |
| 2019-12-31 | $0.12B | +$0.00B | +3.79% |
| 2018-12-31 | $0.11B | +$0.01B | +10.82% |
| 2017-12-31 | $0.10B | -$0.00B | -2.40% |
| 2016-12-31 | $0.10B | -$0.01B | -8.95% |
Compare revenue vs peers
Medical - DevicesCompare LAB revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Standard BioTools Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Standard BioTools Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Standard BioTools Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
LAB revenue · 4 questionsLAB's trailing twelve-month (TTM) revenue is $0.09B. That is a decrease of 51.08% year-over-year from $0.09B in FY2025.
▸ Source: FMP · Standard BioTools Inc. SEC filings · GAAP · Standard BioTools Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026